Stock Analysis
- United Kingdom
- /
- Pharma
- /
- LSE:HIK
Hikma Pharmaceuticals First Half 2023 Earnings: EPS: US$0.59 (vs US$0.76 in 1H 2022)
Hikma Pharmaceuticals (LON:HIK) First Half 2023 Results
Key Financial Results
- Revenue: US$1.43b (up 18% from 1H 2022).
- Net income: US$131.0m (down 24% from 1H 2022).
- Profit margin: 9.2% (down from 14% in 1H 2022).
- EPS: US$0.59 (down from US$0.76 in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hikma Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - Hikma Pharmaceuticals has 3 warning signs we think you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Hikma Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About LSE:HIK
Hikma Pharmaceuticals
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.